Telix Pharmaceuticals Welcomes New Chief Technology Officer
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) has made a significant move by appointing Dr. Paul Schaffer to the position of Chief Technology Officer (CTO). This decision marks an important step for Telix as it continues to enhance its leadership team in the field of radiopharmaceuticals.
Dr. Paul Schaffer: A Leader in Life Sciences Technology
Before joining Telix, Dr. Schaffer held the position of CTO at ARTMS Inc., a company that was acquired by Telix in 2024. With over seven years of experience at ARTMS, along with his role as Director of Life Science at TRIUMF, Canada’s renowned particle accelerator research hub, Dr. Schaffer brings a wealth of knowledge and expertise to his new role. He has played a pivotal role in advancing TRIUMF's Life Sciences program, leading to the development of significant radiochemistry facilities and the ARTMS QUANTM Irradiation System® (QIS®), which focuses on large-scale isotope production.
Driving Innovation at Telix
In his new capacity as CTO, Dr. Schaffer will leverage his extensive background to propel Telix's capabilities in radiopharmaceutical research and clinical applications. This role encompasses a broad spectrum of responsibilities, including advancements in chemistry, physics, artificial intelligence (AI), dosimetry, and data analytics. He will be key in reinforcing the work of Telix’s Chief Scientist, Dr. Michael Wheatcroft, and the dedicated research and development team aimed at advancing innovations in healthcare.
Commitment to Transforming Patient Care
Dr. Schaffer expressed his enthusiasm for the new challenges ahead, stating, "I’m excited to be taking on this role at such a pivotal time for Telix. The company is making meaningful strides toward its mission of improving patient outcomes through innovative therapies. I look forward to collaborating with this talented team to propel R&D for the technologies that will define the next generation of radiotherapeutics." His vision reflects a commitment to not just meet but exceed the expectations within the industry.
Support from Telix Leadership
Dr. Christian Behrenbruch, who serves as Telix Managing Director and Group Chief Executive Officer, praised Dr. Schaffer's appointment, citing his impressive background in life sciences technology and his groundbreaking contributions to isotope production. Behrenbruch mentioned, "Having observed Paul’s remarkable intellect and innovative ideas at TRIUMF and ARTMS, I am thrilled to welcome him to the broader Telix team. His expertise will be invaluable as we continue to push the boundaries of radiopharmaceutical innovation." This sentiment within the leadership echoes the company’s commitment to excellence and innovation in drug development.
About Telix Pharmaceuticals
Telix is a leading biopharmaceutical company specializing in the development and commercialization of therapeutic and diagnostic radiopharmaceuticals, along with related medical technologies. Headquartered in Melbourne, Australia, Telix has established a global presence, operating in countries such as the United States, Brazil, and Japan. The company is dedicated to addressing critical unmet medical needs in oncology and rare diseases with its diverse portfolio of clinical and commercial-stage products. The Telix Group includes several affiliated companies focused on advancing the field of radiopharmaceuticals.
Contact Information
For more information about Telix Pharmaceuticals and its latest developments, individuals can reach out to Ms. Kyahn Williamson, the Senior Vice President of Investor Relations and Corporate Communications. She can be contacted via email at kyahn.williamson@telixpharma.com.
Frequently Asked Questions
What role has Dr. Paul Schaffer taken at Telix Pharmaceuticals?
Dr. Paul Schaffer has been appointed as the Chief Technology Officer at Telix Pharmaceuticals, where he will lead technological advancements in radiopharmaceuticals.
What experience does Dr. Schaffer bring to Telix?
Previously, Dr. Schaffer was the CTO at ARTMS Inc. and has significant experience at TRIUMF, where he contributed to innovative life sciences technologies.
How is Telix Pharmaceuticals positioned in the market?
Telix is focused on developing therapeutic and diagnostic radiopharmaceuticals and has a strong international presence, addressing critical medical needs in oncology and rare diseases.
What are the key areas of focus for Dr. Schaffer at Telix?
Dr. Schaffer will concentrate on enhancing capabilities in chemistry, physics, AI, dosimetry, and data analytics to advance research and development.
How can investors learn more about Telix Pharmaceuticals?
Investors can learn more about Telix's developments and latest information by reaching out to their investor relations team or visiting their official website.
